Remicade Related Published Studies
Well-designed clinical trials related to Remicade (Infliximab)
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. [2008.10]
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. [2008.09.15]
Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. [2008.09]
Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). [2008.08.22]
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. [2008.08]
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. [2008.06]
Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. [2008.06]
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. [2008.06]
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). [2008.05]
A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. [2008.05]
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. [2008.04]
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. [2008.03]
Efficacy of Infliximab in Extrapulmonary Sarcoidosis: Results from a Randomized Trial. [2008.02.06]
A review of infliximab use in ulcerative colitis. [2008.02]
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. [2008.02]
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. [2008.01]
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. [2008.01]
Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. [2007.12.28]
Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. [2007.11.29]
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. [2007.11]
The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. [2007.10.08]
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. [2007.09]
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. [2007.09]
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. [2007.09]
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. [2007.09]
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. [2007.08]
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. [2007.07.30]
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. [2007.07]
Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. [2007.07]
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. [2007.07]
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. [2007.06.19]
Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. [2007.06]
Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. [2007.05.01]
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. [2007.05.01]
Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. [2007.05]
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. A Randomized Trial. [2007.04.30]
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. [2007.04]
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. [2007.03]
Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease. [2007.02.25]
Predictors of early response to infliximab in patients with ulcerative colitis. [2007.02]
The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. [2007]
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. [2006.12]
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. [2006.12]
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through one year of treatment: results from the IMPACT 2 trial. [2006.11.17]
The treatment of disc herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. [2006.11.15]
Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. [2006.11]
IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. [2006.09]
Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. [2006.08.15]
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. [2006.08]
Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. [2006.06]
Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. [2006.05]
Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. [2006.04.15]
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. [2006.04]
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. [2006.04]
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. [2006.04]
Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. [2006.04]
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. [2006.03]
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. [2006.03]
A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. [2006.01]
Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. [2006.01]
Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. [2006.01]
The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. [2005.12.15]
Infliximab for induction and maintenance therapy for ulcerative colitis. [2005.12.08]
Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. [2005.12]
Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. [2005.11]
Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. [2005.11]
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. [2005.10.15]
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. [2005.10]
First study of infliximab treatment in patients with chronic obstructive pulmonary disease. [2005.08.15]
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. [2005.08]
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. [2005.06]
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. [2005.05]
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. [2005.05]
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. [2005.04]
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). [2005.04]
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. [2005.04]
Local injection of Infliximab for the treatment of perianal Crohn's disease. [2005.04]
Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. [2005.04]
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). [2005.02]
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. [2005.02]
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. [2005.01]
Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. [2004.12]
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. [2004.11]
Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. [2004.11]
[Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12] [2004.10]
Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. [2004.10]
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. [2004.10]
Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. [2004.09.01]
Infliximab in the treatment of steroid-dependent ulcerative colitis. [2004.09]
A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. [2004.09]
The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). [2004.09]
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. [2004.07]
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. [2004.05]
Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). [2004.04]
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. [2004.04]
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. [2004.04]
Infliximab maintenance therapy for fistulizing Crohn's disease. [2004.02.26]
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. [2004.02]
Infliximab in active early rheumatoid arthritis. [2004.02]
The effects of infliximab maintenance therapy on health-related quality of life. [2003.10]
Role of adalimumab in the treatment of early rheumatoid arthritis. [2003.09]
|
